[go: up one dir, main page]

AU2001292579A1 - Methods and compounds for treating proliferative diseases - Google Patents

Methods and compounds for treating proliferative diseases

Info

Publication number
AU2001292579A1
AU2001292579A1 AU2001292579A AU9257901A AU2001292579A1 AU 2001292579 A1 AU2001292579 A1 AU 2001292579A1 AU 2001292579 A AU2001292579 A AU 2001292579A AU 9257901 A AU9257901 A AU 9257901A AU 2001292579 A1 AU2001292579 A1 AU 2001292579A1
Authority
AU
Australia
Prior art keywords
compounds
methods
proliferative diseases
treating proliferative
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292579A
Inventor
Stephen Lyle Briggs
Harold Burns Brooks
David Keyes Clawson
Thomas Albert Engler
Kelly Wayne Furness
Sushant Malhotra
Concepcion Sanchez-Martinez
Faming Zhang
Guoxin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001292579A1 publication Critical patent/AU2001292579A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The compounds disclosed herein are indolocarbazoles of Formula (I), which are potent CDK4 inhibitors, and are useful in the treatment of cell proliferative disorders, including cancer. Formula (I).
AU2001292579A 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases Abandoned AU2001292579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23661600P 2000-09-29 2000-09-29
US60/236,616 2000-09-29
PCT/US2001/027728 WO2002028861A2 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
AU2001292579A1 true AU2001292579A1 (en) 2002-04-15

Family

ID=22890242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292579A Abandoned AU2001292579A1 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Country Status (10)

Country Link
US (1) US7109229B2 (en)
EP (1) EP1325011B1 (en)
AT (1) ATE266031T1 (en)
AU (1) AU2001292579A1 (en)
DE (1) DE60103171T2 (en)
DK (1) DK1325011T3 (en)
ES (1) ES2220811T3 (en)
PT (1) PT1325011E (en)
TR (1) TR200401316T4 (en)
WO (1) WO2002028861A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
RU2009119394A (en) 2006-12-07 2011-01-20 Ф. Хоффманн-Ля Рош Аг (Ch) SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS
CA2673307A1 (en) 2006-12-22 2008-07-03 F. Hoffman-La Roche Ag Spiro-piperidine derivatives
AU2009310352A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
CN102231984A (en) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP2012509282A (en) * 2008-11-19 2012-04-19 セファロン、インク． New forms of indazolo [5,4-A] pyrrolo [3,4-C] carbazole compounds
EP3025724B1 (en) 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
KR101815332B1 (en) * 2010-05-18 2018-01-04 세파론, 인코포레이티드 Method for purifying a fused pyrrolocarbazole derivative
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217964A1 (en) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazole imides and their use
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
US20040048915A1 (en) 2004-03-11
ES2220811T3 (en) 2004-12-16
WO2002028861A3 (en) 2002-08-01
DE60103171D1 (en) 2004-06-09
WO2002028861A2 (en) 2002-04-11
PT1325011E (en) 2004-09-30
TR200401316T4 (en) 2004-07-21
EP1325011A2 (en) 2003-07-09
US7109229B2 (en) 2006-09-19
WO2002028861A8 (en) 2003-11-20
EP1325011B1 (en) 2004-05-06
DK1325011T3 (en) 2004-08-16
DE60103171T2 (en) 2004-11-11
ATE266031T1 (en) 2004-05-15

Similar Documents

Publication Publication Date Title
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
MXPA03006863A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors.
MY151032A (en) Treatment of tnf? related disorders
MX2007001986A (en) Aminoheteroaryl compounds as protein tyrosine kinase inhibitors.
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA05014166A (en) Methods and compositions for treating amyloid-related diseases.
BR0215360A (en) Indoline derivatives useful as protein kinase inhibitors
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
AU2003252025A1 (en) Compounds, compositions, and methods
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
NO20003848D0 (en) Method of Treating Follicular Lymphoma Using Lymphotoxin (LT) Pathway Inhibitors
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
JO2199B1 (en) Substituted pyrroles